Ten years ago, a consensus report on the optimization of tacrolimus was published in this
journal. In 2017, the Immunosuppressive Drugs Scientific Committee of the International …

The calcineurin‐inhibitor tacrolimus (Tac) provides an acceptable balance between
prevention of allograft rejection and drug‐related adverse effects, making it the standard of …

Short-term patient and graft outcomes continue to improve after kidney and liver
transplantation, with 1-year survival rates over 80%; however, improving longer-term …

Background Lack of adherence to immunosuppressive drugs is a risk factor for development
of de novo donor-specific antibodies (dnDSA) and can contribute to antibody-mediated …

Background Following solid organ transplantation, tacrolimus (TAC) is an essential drug in
the immunosuppressive strategy. Its use constitutes a challenge due to its narrow …

Tacrolimus is a critical dose drug with a considerable intrapatient variability (IPV) in its
pharmacokinetics. We investigated whether a high IPV in tacrolimus exposure is associated …

Disorder and noise are inherent in biological systems. They are required to provide systems
with the advantages required for proper functioning. Noise is a part of the flexibility and …

The purpose of this study was to determine the intrapatient (within the same patient)
variability of tacrolimus in adherent patients. Daily tacrolimus trough levels were obtained at …

Cannabidiol (CBD), a major purified nonpsychoactive component of cannabis with
anticonvulsant properties, was approved by the US Food and Drug Administration (FDA) in …

Tacrolimus exhibits low and variable drug exposure after oral dosing, but the contributing
factors remain unclear. Based on our recent report showing a positive correlation between …